LIFE Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States...

Stats
Today's Volume	209 922
Average Volume	546 155
Market Cap	119.39M
EPS	$0 ( 2024-05-14 )
Next earnings date	( $-0.220 ) 2024-08-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.970
ATR14	$0.00700 (0.40%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-22	Clarke John K	Buy	24 000	Stock Option (right to buy)
2024-05-22	Gross Jane A	Buy	24 000	Stock Option (right to buy)
2024-05-22	Lucas Svetlana	Buy	24 000	Stock Option (right to buy)
2024-05-22	Schimmel Paul	Buy	24 000	Stock Option (right to buy)
2024-05-22	Zaknoen Sara	Buy	24 000	Stock Option (right to buy)

INSIDER POWER
93.63
Last 99 transactions
Buy: 4 185 378 \| Sell: 335 227

Volume Correlation

Long: 0.23 (neutral)

Short: 0.37 (neutral)

Signal:(58.094) Neutral

aTyr Pharma Inc Correlation

10 Most Positive Correlations
RDWR	0.803

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

aTyr Pharma Inc Correlation - Currency/Commodity

-0.50
( weak negative )

-0.40
( neutral )

0.00
( neutral )

-0.43
( neutral )

0.66
( moderate )

aTyr Pharma Inc Financials

Annual	2023
Revenue:	$353 000
Gross Profit:	$-2.39M (-676.49 %)
EPS:	$-0.940

FY	2023
Revenue:	$353 000
Gross Profit:	$-2.39M (-676.49 %)
EPS:	$-0.940

FY	2022
Revenue:	$10.39M
Gross Profit:	$8.69M (83.68 %)
EPS:	$-1.560

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.770

Financial Reports:

No articles found.

aTyr Pharma Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

aTyr Pharma Inc

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.